Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012827 | 0.91 | MAPK14 (0.45) | EPHX2MAPK14BRAFFAAHTRPV1 | |
| SCHEMBL1012497 | 0.90 | RAF1 (0.45) | MAPK14BRAFALDH1A1MAPTKMT2A | |
| SCHEMBL23966924 | 0.87 | BRAF (0.47) | MAPK14BRAFALDH1A1MAPTKMT2A | |
| SCHEMBL1013171 | 0.86 | ALDH1A1 (0.56) | MAPK14BRAFFAAHALDH1A1MAPT | |
| SCHEMBL1013308 | 0.84 | RAF1 (0.47) | MAPK14BRAFALDH1A1MAPTKMT2A | |
| SCHEMBL1011942 | 0.82 | CNR2 (0.47) | MAPK14ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL1014233 | 0.81 | CNR2 (0.47) | MAPK14BRAFALDH1A1MAPTKMT2A | |
| SCHEMBL1011650 | 0.80 | CNR2 (0.50) | MAPK14BRAFALDH1A1MAPTKMT2A | |
| SCHEMBL1895964 | 0.79 | ALDH1A1 (0.53) | EPHX2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL23966917 | 0.79 | FAAH (0.46) | BRAFFAAHTRPV1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662206-A1 | GSPT1 DEGRADER COMPOUNDS | Captor Therapeutics S.A. (PL) | 2025-12-17 | — | — | EP | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2024165577-A1 | GSPT1 DEGRADER COMPOUNDS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-08-15 | — | — | WO | disclosed |
| EP-4146348-B1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| EP-1611128-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | Pharmacia & Upjohn Company LLC (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085433-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | EPHX2 2132/4885MAPK14 80/4885BRAF 1/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | EPHX2 1702/4885MAPK14 447/4885BRAF 507/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | EPHX2 1883/4885MAPK14 454/4885BRAF 578/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | EPHX2 1883/4885MAPK14 454/4885BRAF 578/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EPHX2 1990/4885MAPK14 717/4885BRAF 1615/4885 |
| US-20230416259-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | EPHX2 1883/4885MAPK14 454/4885BRAF 578/4885 |
| US-20080132551-A1 | Positive allosteric modulators of the nicotinic acetylcholine receptor | CHRNA1, CHRNA7, CHRNA5 | EPHX2 1902/4885MAPK14 3063/4885BRAF 4259/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | EPHX2 1933/4885MAPK14 145/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.